摘要
目的了解2015年1月1日—2021年12月31日CHINET耐药监测网变形杆菌属、摩根菌属和普罗威登菌属细菌分布及耐药性变化。方法按CHINET统一方案进行药物敏感性试验。按CLSI M10031st 2021年版折点标准判断结果。结果7年间共监测收集到肠杆菌目摩根菌科细菌32433株,其中变形杆菌属24160株,摩根菌属6704株,普罗威登菌属1569株,细菌数量呈增长趋势。标本分布前三位依次为尿液、下呼吸道和伤口分泌物。三种菌属细菌对阿米卡星、美罗培南、头孢西丁、头孢吡肟、头孢哌酮-舒巴坦和哌拉西林-他唑巴坦的耐药率均较低,其中变形杆菌属和摩根菌属对受测试抗菌药物的耐药率大多<10%,普罗威登菌属的耐药率大多<20%。变形杆菌属、摩根菌属和普罗威登菌属中的碳青霉烯类耐药菌株检出率分别为1.4%、1.9%和15.6%。结论变形杆菌属、摩根菌属和普罗威登菌属临床分离菌株近年有明显增加趋势;这些菌株中碳青霉烯类耐药菌株的检出亦有明显增多。应加强关注,重视细菌耐药监测,合理用药,防止耐药细菌的发生和耐药率上升。
Objective To understand the changing distribution and antimicrobial resistance profiles of Proteus,Morganella and Providencia in hospitals across China from January 1,2015 to December 31,2021 in the CHINET Antimicrobial Resistance Surveillance Program.Methods Antimicrobial susceptibility testing was carried out following the unified CHINET protocol.The results were interpreted in accordance with the breakpoints in the 2021 Clinical&Laboratory Standards Institute(CLSI)M100(31st Edition).Results A total of 32433 Enterobacterales strains were isolated during the 7-year period,including 24160 strains of Proteus,6704 strains of Morganella,and 1569 strains of Providencia.The overall number of these Enterobacterales isolates increased significantly over the 7-year period.The top 3 specimen source of these strains were urine,lower respiratory tract specimens,and wound secretions.Proteus,Morganella,and Providencia isolates showed lower resistance rates to amikacin,meropenem,cefoxitin,cefepime,cefoperazone-sulbactam,and piperacillin-tazobactam.For most of the antibiotics tested,less than 10%of the Proteus and Morganella strains were resistant,while less than 20%of the Providencia strains were resistant.The prevalence of carbapenemresistant Enterobacterales(CRE)was 1.4%in Proteus isolates,1.9%in Morganella isolates,and 15.6%in Providencia isolates.Conclusions The overall number of clinical isolates of Proteus,Morganella and Providencia increased significantly in the 7-year period from 2015 to 2021.The prevalence of CRE strains also increased.More attention should be paid to antimicrobial resistance surveillance and rational antibiotic use so as to prevent the emergence and increase of antimicrobial resistance.
作者
许云敏
董小雪
单斌
杨洋
胡付品
朱德妹
徐英春
张小江
季萍
张峰波
谢轶
康梅
王传清
付盼
徐元宏
黄颖
孙自镛
陈中举
倪语星
孙景勇
褚云卓
田素飞
胡志东
李金
俞云松
林洁
郭素芳
魏莲花
邹凤梅
张泓
王春
胡云建
艾效曼
卓超
苏丹虹
郭大文
赵金英
喻华
黄湘宁
刘文恩
李艳明
金炎
邵春红
徐雪松
鄢超
王山梅
楚亚菲
张利侠
马娟
周树平
周艳
朱镭
孟晋华
董芳
郑红艳
胡芳芳
沈瀚
周万青
贾伟
李刚
吴劲松
卢月梅
李继红
段金菊
康建邦
马晓波
郑燕萍
郭如意
朱焱
陈运生
孟青
王世富
胡雪飞
沈继录
黄文辉
汪瑞忠
房华
俞碧霞
赵勇
龚萍
温开镇
张贻荣
刘江山
廖龙凤
顾洪芹
姜琳
贺雯
薛顺虹
冯佼
岳春雷
XU Yunmin;DONG Xiaoxue;SHAN Bin;YANG Yang;HU Fupin;ZHU Demei;XU Yingchun;ZHANG Xiaojiang;JI Ping;ZHANG Fengbo;XIE Yi;KANG Mei;WANG Chuanqing;FU Pan;XU Yuanhong;HUANG Ying;SUN Ziyong;CHEN Zhongju;NI Yuxing;SUN Jingyong;CHU Yunzhuo;TIAN Sufei;HU Zhidong;LI Jin;YU Yunsong;LIN Jie;GUO Sufang;WEI Lianhua;ZOU Fengmei;ZHANG Hong;WANG Chun;HU Yunjian;AI Xiaoman;ZHUO Chao;SU Danhong;GUO Dawen;ZHAO Jinying;YU Hua;HUANG Xiangning;LIU Wen'en;LI Yanming;JIN Yan;SHAO Chunhong;XU Xuesong;YAN Chao;WANG Shanmei;CHU Yafei;ZHANG Lixia;MA Juan;ZHOU Shuping;ZHOU Yan;ZHU Lei;MENG Jinhua;DONG Fang;ZHENG Hongyan;HU Fangfang;SHEN Han;ZHOU Wanqing;JIA Wei;LI Gang;WU Jinsong;LU Yuemei;LI Jihong;DUAN Jinju;KANG Jianbang;MA Xiaobo;ZHENG Yanping;GUO Ruyi;ZHU Yan;CHEN Yunsheng;MENG Qing;WANG Shifu;HU Xuefei;SHEN Jilu;HUANG Wenhui;WANG Ruizhong;FANG Hua;YU Bixia;ZHAO Yong;GONG Ping;WEN Kaizhen;ZHANG Yirong;LIU Jiangshan;LIAO Longfeng;GU Hongqin;JIANG Lin;HE Wen;XUE Shunhong;FENG Jiao;YUE Chunlei(Department of Laboratory Medicine,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)
出处
《中国感染与化疗杂志》
CAS
CSCD
北大核心
2024年第4期410-417,共8页
Chinese Journal of Infection and Chemotherapy
基金
CHINET中国细菌耐药监测网基金(2020QD049)。